Trial Profile
A Phase I-II Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 11 Apr 2022
Price :
$35
*
At a glance
- Drugs Cytarabine (Primary) ; Idarubicin (Primary) ; Nintedanib (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 12 Aug 2021 Status changed from active, no longer recruiting to completed.
- 14 Jul 2021 Planned primary completion date changed from 1 Jun 2021 to 1 Aug 2021.
- 14 Jul 2021 Status changed from recruiting to active, no longer recruiting.